1. Protection from infection and reinfection due to the Omicron BA.1 variant in care homes
- Author
-
Saher Choudhry, Thomas A. J. Rowland, Kamil McClelland, Erik Renz, Nalini Iyanger, J Yimmy Chow, Felicity Aiano, Shamez N. Ladhani, Anna Jeffery-Smith, Nick J. Andrews, and Maria Zambon
- Subjects
COVID-19 ,SARS-CoV-2 ,Omicron (BA1) ,care homes ,outbreaks ,correlate of protection ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionFollowing the emergence of SARS-CoV-2 in 2020, care homes were disproportionately impacted by high mortality and morbidity of vulnerable elderly residents. Non-pharmaceutical interventions (NPIs) and improved infection control measures together with vaccination campaigns have since improved outcomes of infection. We studied the utility of past infection status, recent vaccination and anti-S antibody titres as possible correlates of protection against a newly emergent Omicron variant infection.MethodsProspective longitudinal surveillance of nine sentinel London care homes from April 2020 onwards found that all experienced COVID-19 outbreaks due to Omicron (BA.1) during December 2021 and January 2022, despite extensive prior SARS-CoV-2 exposure and high COVID-19 vaccination rates, including booster vaccines (>70% residents, >40% staff).ResultsDetailed investigation showed that 46% (133/288) of Omicron BA.1 infections were SARS-CoV-2 reinfections. Two and three COVID-19 vaccine doses were protective against Omicron infection within 2-9 weeks of vaccination, though protection waned from 10 weeks post-vaccination. Prior infection provided additional protection in vaccinated individuals, approximately halving the risk of SARS-CoV-2 infection.DiscussionAnti-S antibody titre showed a dose-dependent protective effect but did not fully account for the protection provided by vaccination or past infection, indicating that other mechanisms of protection are also involved.
- Published
- 2023
- Full Text
- View/download PDF